Skip to main content
. Author manuscript; available in PMC: 2015 Mar 11.
Published in final edited form as: Circulation. 2014 Jan 6;129(10):1139–1151. doi: 10.1161/CIRCULATIONAHA.113.002416

Figure 1.

Figure 1

TSA and SAHA reduce infarct size and preserve systolic function in mouse I/R. a. Representative TTC staining of TSA and DMSO pretreatment groups after I/R (45 min/24 hour). White: Infarct, Red: AAR, Blue: Remote. b. TSA reduced infarct (IF) size normalized to area at risk (AAR) (n=11, p<0.05) as determined by TTC staining after I/R. c. There were no significant differences in AAR among groups. d. TSA reduced IF normalized to left ventricle weight (LV) (n=11, p<0.05). e. TSA daily injection for up to total 14 days treatment improved systolic function measured as %FS after I/R (n =10, p<0.05). f. Representative TTC staining of SAHA and DMSO pretreatment groups after I/R (45 min/24 hour) g. SAHA pretreatment before I/R (50 mg/kg, SAHA50) reduced IF/AAR significantly (n=6-7, p<0.05). SAHA at a lower dose (30 mg/kg, SAHA30) did not achieve statistical significance. h. There were no significant differences in AAR among groups. i. SAHA treatment partially preserved %FS measured by echocardiography after I/R (n=6-7, p<0.05).